Education
About Us
Working with TipRanks
Follow Us
Renovorx, Inc. (RNXT)
:RNXT
RNXT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.75 - $1.69
Previous CloseN/A
Volume39.72K
Average Volume (3M)101.29K
Market Cap
$37.28M
Enterprise Value$24.13M
Total Cash (Recent Filing)-$2.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.62
Next Earnings
May 19, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding36,546,753
10 Day Avg. Volume156,122
30 Day Avg. Volume101,294
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.48
Forecast
1Y Price Target
$3.00Price Target Upside194.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe company is on track to complete enrollment in the 114-patient Phase 3 TIGeR-PaC study, which is crucial for advancing its treatment for pancreatic cancer.
Market PotentialWith a total addressable worldwide market of approximately $740M, if successful, the company could generate significant revenues.
Revenue GenerationRenovoCath realizes first revenues, marking a significant milestone for the company.
Bears Say
Earnings ReportRenovoRx reported 3Q24 results with a net loss of ($2.4M) and ended the period with $9.5M in cash on the balance sheet, which should provide runway into 1H25.
Financial PerformanceThe company reported a net loss of $0.40 per diluted share for the fourth quarter.
Shareholder ValueThe current valuation is considered attractive, with a raised 12-month price target to $9.00, representing significant upside from the current share price.
---
Ownership Overview
4.27%
Insiders
1.13% Mutual Funds
0.27% Other Institutional Investors
91.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RNXT FAQ
What was Renovorx, Inc.’s price range in the past 12 months?
Renovorx, Inc. lowest stock price was $0.75 and its highest was $1.69 in the past 12 months.
What is Renovorx, Inc.’s market cap?
Renovorx, Inc.’s market cap is $37.28M.
When is Renovorx, Inc.’s upcoming earnings report date?
Renovorx, Inc.’s upcoming earnings report date is May 19, 2025 which is in 28 days.
How were Renovorx, Inc.’s earnings last quarter?
Renovorx, Inc. released its earnings results on Apr 01, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.04.
Is Renovorx, Inc. overvalued?
According to Wall Street analysts Renovorx, Inc.’s price is currently Undervalued.
Does Renovorx, Inc. pay dividends?
Renovorx, Inc. does not currently pay dividends.
What is Renovorx, Inc.’s EPS estimate?
Renovorx, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Renovorx, Inc. have?
Renovorx, Inc. has 36,546,753 shares outstanding.
What happened to Renovorx, Inc.’s price movement after its last earnings report?
Renovorx, Inc. reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Renovorx, Inc.?
Currently, no hedge funds are holding shares in RNXT
---
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (194.12% Upside)
$3.00 (194.12% Upside)
Blogger Sentiment
Bullish
RNXT Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $119.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.28%
12-Months-Change
Fundamentals
Return on Equity
-1192.69%
Trailing 12-Months
Asset Growth
459.14%
Trailing 12-Months
Company Description
Renovorx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
---
RNXT Stock 12 Month Forecast
Average Price Target
$3.00
▲(194.12% Upside)
Technical Analysis
Tempest Therapeutics
―
Rein Therapeutics
―
ALX Oncology Holdings
―
Surrozen
―
MiNK Therapeutics
―
Best Analysts Covering RNXT
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-39.94%
reiterated a buy rating 5 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -39.94% per trade.
---